COMPANY PROFILE · UPDATED 18 NOV 2025

AsclepiX Therapeutics

AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways. Their peptide…

asclepix.com ↗

This profile is unclaimed — do you work here? Claim it

Claim it →

Founded: 2011
Headcount: 18
Open roles: 0
Last raised: Series A · Sign in to view

LEADERSHIP

Founders & key people

Wendy Perrow

CEO at Alba Therapeutics

Alba TherapeuticsFemasysUSM Maryland Momentum FundPrinceton Capital AdvisorsBioanalytical SystemsAsclepiX TherapeuticsFuqua School of BusinessDuke UniversityEastern Illinois University

Jordan Green

Researcher

AsclepiX TherapeuticsJohns Hopkins UniversityMassachusetts Institute of Technology (MIT)Momenta PharmaceuticalsMassachusetts Institute of Technology (MIT)

Aleksander S. Popel

American university teacher

AsclepiX TherapeuticsJohns Hopkins UniversityHarvard UniversityHopkins UniversityMassachusetts Institute of Technology (MIT)МГУ

OPEN ROLES

Hiring at AsclepiX Therapeutics

No open roles listed right now. Check back soon or search all jobs →

FUNDING

Capital raised

Total Amount Raised: $50,000,000

AsclepiX Therapeutics Funding Rounds

Series A
$10M
Jul 26, 2023
Series A
$10M
Jul 25, 2023
Series A Investors
Perceptive Advisors
Rapha Capital Management
Hibiscus Capital Management
Series A
$35M
Jun 24, 2020
Series A
$35M
Jun 23, 2020
Series A Investors
Perceptive Advisors
Rapha Capital Management
Barer & Son Capital
Convertible Note
$5M
Nov 13, 2018
Convertible Note
$5M
Nov 12, 2018
Convertible Note Investors
Barer & Son Capital
TEDCO
Piedmont Capital Partners
Salem Partners
Rapha Capital Management